Stay updated on Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    A 403 Forbidden error page is now shown when accessing the study record, replacing the previous content. The page includes a 403 message and a Home link, indicating access is denied rather than study details.
    Difference
    0.5%
    Check dated 2026-09-28T22:42:35.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study content with an access-denied message. The header and navigation remain visible while the study details are no longer accessible, indicating an access issue rather than new content.
    Difference
    18%
    Check dated 2026-09-21T22:50:36.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The study page now lists related topics: Lung cancer and MedlinePlus Genetics. This improves access to disease- and genetics-related resources from the study record.
    Difference
    0.2%
    Check dated 2026-09-14T19:50:38.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The related topics block including 'Lung cancer', 'related topics:', and 'MedlinePlus Genetics' is removed from the page, reducing quick-access consumer health links.
    Difference
    0.2%
    Check dated 2026-09-07T20:22:56.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    Added related topics sections for Lung cancer and MedlinePlus Genetics and updated the page revision tag to v3.6.6 (replacing v3.6.5). These changes affect metadata and navigation but do not modify the core study details or functionality.
    Difference
    0.2%
    Check dated 2026-08-31T16:46:28.000Z thumbnail image
  7. Check
    46 days ago
    Change Detected
    Summary
    An NIH grant/contract funding note was added to the study's identifiers, clarifying the funding source behind the trial. This addition provides funding transparency but does not alter study design, endpoints, or participant information.
    Difference
    0.1%
    Check dated 2026-08-24T18:06:07.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.